<DOC>
	<DOCNO>NCT02663141</DOCNO>
	<brief_summary>The aim study determine whether oral losartan effective treatment diabetic macular edema ( DME ) adjuvant intravitreal bevacizumab ( IVB ) .</brief_summary>
	<brief_title>Randomized Clinical Trial Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan Treatment Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>All type 2 diabetes mellitus patient clinically significant macular edema ( CSME ) , except mention exclusion criterion 1 . Patients Uncontrolled hypertension 2 . Patients Proliferative diabetic retinopathy 3 . Patients Who receive angiotensin convert enzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARB ) 4 . Previous treatment diabetic retinopathy ( e.g. , laser photocoagulation , photodynamic therapy , intravitreal injection steroid , antivascular endothelial growth factor , retinal surgery ) 5. medium opacity 6. evidence ocular disease ( e.g. , glaucoma , uveitis , age relate macular degeneration etc. , ) 7 . Pathologic myopia &gt; 6 Diopter 8 . Patients poor fixation cooperation 9 . Patients renal cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>